Table 1.
Survival distribution inputs.
| Pazopanib | Placebo | Reference | |
|---|---|---|---|
| Weibull survival function parameters | |||
| PFS (months) | |||
| Lambda | 0.1279 | 0.3714 | PALETTE |
| Gamma | 1.1252 | 1.0809 | PALETTE |
| OS (months) | |||
| Lambda | 0.0282 | 0.0469 | PALETTE |
| Gamma | 1.2341 | 1.1027 | PALETTE |
| PPS (months) | |||
| Lambda | 0.104 | 0.118 | PALETTE |
| Gamma | 0.902 | 0.898 | PALETTE |
| Probability of death without disease progression (required for Markov cohort model)a |
0.053 | 0 | PALETTE |
| HR for PFS for pazopanib versus comparator | |||
| Ifosfamide | 0.91 (95% CI, 0.73–1.14) | Sharma et al. 2013 [18] van Oosterom et al. 2002 [43] |
|
| Trabectedin | 0.90 (95% CI, 0.76–1.07) | Sharma et al. 2013 [18] Demetri et al. 2009 [44] Garcia-Carbonero et al. 2005 [45] le Cesne et al. 2005 [46] Yovine et al. 2004 [47] |
|
| Gemcitabine + docetaxel | 0.99 (95% CI, 0.70–1.40) | Sharma et al. 2013 [18] Hensley et al. 2008 [48] Pautier et al. 2012 [33] |
|
CI: confidence interval; HR: hazard ratio; OS: overall survival; PFS: progression-free survival; PPS: postprogression survival.
aSame value was assumed for chemotherapies in indirect comparison.